Zebrafish Dyslipidemia Models

Introduction

Dyslipidemia refers to abnormal lipid metabolism characterized by elevated total cholesterol, triglycerides, LDL/VLDL, reduced HDL, or altered lipid transport and storage. It is a major contributor to atherosclerosis, fatty liver disease, obesity-related metabolic dysfunction, diabetes complications, and cardiovascular disease. Clinically, dyslipidemia is often asymptomatic in the early stage but may progress to vascular lipid deposition, endothelial dysfunction, hepatic steatosis, chronic inflammation, and increased cardiovascular risk. It is common in adults with obesity, insulin resistance, unhealthy diets, sedentary lifestyles, genetic lipid disorders, or metabolic syndrome.

Current management includes statins, cholesterol absorption inhibitors, PCSK9-targeting therapies, fibrates, omega-3 fatty acids, lifestyle intervention, and dietary supplements. However, drug response, residual cardiovascular risk, hepatometabolic safety, and long-term efficacy remain important research challenges. Zebrafish dyslipidemia models provide a practical in vivo system to evaluate lipid absorption, cholesterol and triglyceride regulation, hepatic lipid accumulation, vascular lipid deposition, and lipid-lowering efficacy. These models are increasingly used for early drug discovery, nutraceutical screening, mechanism studies, and translational metabolic disease research.

Why Zebrafish?

• Conserved Lipid Metabolism: Conserved lipid metabolism pathways support translational dyslipidemia research.
• Direct Imaging: Optical transparency enables direct imaging of lipid accumulation and vascular changes.
• High-Throughput Screening: Small size allows medium- to high-throughput lipid-lowering compound screening.
• Diet-Induced Phenotypes: Diet-induced hyperlipidemia phenotypes can be established rapidly and reproducibly.
• Integrated Endpoints: Multiple endpoints can be integrated in the same in vivo study.

Available Zebrafish Disease Models

Our models span dietary, larval absorption, and fatty-liver configurations across the lipid-metabolism spectrum:

Phenotypic Evaluation

Key Applications

• Lipid-Lowering Drug Screening: Rapid in vivo evaluation of compounds targeting cholesterol, triglycerides, fatty acid absorption, lipid transport, or lipid clearance.
• Nutraceutical and Functional Food Efficacy Testing: Assessment of ingredients designed for blood lipid management, cholesterol reduction, triglyceride control, or metabolic health support.
• Mechanism-of-Action Studies: Investigation of pathways involved in intestinal lipid absorption, hepatic lipid metabolism, bile processing, oxidative lipid modification, and vascular lipid deposition.
• Atherosclerosis and Cardiovascular Risk Research: Modeling of dyslipidemia-associated vascular lipid accumulation, oxidized lipid formation, and inflammatory cell recruitment.
• Fatty Liver and Metabolic Syndrome Research: Evaluation of the link between dyslipidemia, hepatic steatosis, obesity-related lipid dysregulation, and metabolic inflammation.

Study Examples

High-cholesterol diet zebrafish model for vascular lipid accumulation. This study established a hypercholesterolemic zebrafish model using a high-cholesterol diet. The authors examined plasma lipid elevation, vascular lipid deposition, lipoprotein oxidation, and macrophage uptake of modified lipids. Fluorescent lipid tracers and vascular imaging were used to visualize lipid accumulation in live zebrafish. The model reproduced several early features associated with atherogenic dyslipidemia, including oxidized lipid formation and inflammatory cell involvement.

Fig. 1. High-cholesterol feeding induces vascular lipid accumulation and hypercholesterolemia-related phenotypes in zebrafish (Stoletov K, Fang L, et al., 2009).

High-fat overfeeding zebrafish model for dyslipidemia and metabolic syndrome. Adult zebrafish were overfed with Artemia to induce a diet-induced obesity and dyslipidemia phenotype. The model showed increased body mass index, elevated plasma triglycerides, and hepatic steatosis. Calorie restriction reduced body weight and plasma triglyceride levels, supporting model reversibility and treatment responsiveness. Comparative transcriptomic analysis of visceral adipose tissue showed that zebrafish and mammalian obesity share dysregulated pathways related to lipid metabolism, coagulation, and inflammatory regulation.

Fig. 2. Overfeeding induces increased BMI, hypertriglyceridemia, and hepatic lipid accumulation in adult zebrafish (Oka T, Nishimura Y, et al., 2010).

References

1. Stoletov K, Fang L, et al. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circulation Research 104(8), 952–960 (2009).
2. Oka T, Nishimura Y, et al. Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiology 10, 21 (2010).